• Carbapenemase Gene Transmission in CREC, 2022–2024

  2026-09-03

  Chen et al. mapped carbapenemase-encoding genes, their genomic locations, transferability, and strain relatedness among carbapenem-resistant Enterobacter cloacae collected from eight teaching hospitals in Guangdong. The study shows that blaNDM-1 was frequently plasmid associated, readily transferable in laboratory conjugation, and linked to broader multidrug resistance, highlighting the importance of combining molecular surveillance with epidemiological typing.

• Sisomicin Activity Against Clinical Isolates

  2026-09-02

  The reference study evaluated sisomicin against 565 clinical isolates and positioned it against gentamicin, tobramycin, amikacin, butirosin, and kanamycin using standardized broth-dilution testing. Its main contribution was a broad comparative susceptibility profile showing strong activity against most tested gram-negative bacilli, while also identifying cross-resistance patterns and the relative vulnerability of Serratia marcescens.

• ω-Agatoxin IVA TFA: Assay Design Guide

  2026-09-02

  ω-Agatoxin IVA TFA is a precision Cav2.1 probe for separating calcium-current inhibition from downstream changes in synaptic function. This guide translates its subtype selectivity, cardiac vagal neuron evidence, and epilepsy-model data into practical assay decisions.

• Difloxacin HCl Research Workflows

  2026-09-01

  Difloxacin HCl supports two distinct research workflows: standardized antimicrobial susceptibility testing and exploratory multidrug resistance reversal in neuroblastoma models. This guide connects practical formulation, assay design, controls, and troubleshooting with a mechanistic framework for interpreting drug-response experiments.

• Methicillin Sodium Salt: Assay Design for MSSA

  2026-09-01

  Learn how Methicillin sodium salt can support rigorous MSSA susceptibility, resistance, and gram-positive infection model research. This guide translates clinical trial endpoint design into practical assay decisions without confusing in vitro potency with patient-level efficacy.

• Tetracycline Hydrochloride: Bench Workflow Guide

  2026-08-31

  Build more reliable antimicrobial and microbiome experiments with Tetracycline Hydrochloride, from concentration-range finding to orthogonal confirmation of bacteriostasis. The workflow also shows how recent ROS-driven cancer research can sharpen assay controls without conflating bacterial translation inhibition with platinum nanotherapeutic mechanisms.

• Temafloxacin: From Mechanism to Translational Strategy

  2026-08-31

  Temafloxacin offers a useful translational framework for connecting fluoroquinolone target biology, pathogen-specific susceptibility, intracellular assay design, and historical pharmacokinetic evidence. This article outlines how researchers can move beyond product-page spectrum claims toward exposure-aware, mechanism-informed antibacterial workflows.

• Fenofibrate Workflows for PPARα Research

  2026-08-30

  Fenofibrate is a practical PPARα agonist for connecting lipid metabolism with liver growth and YAP pathway biology. This workflow-oriented guide covers solvent handling, time-course assays, age-aware study design, cancer models, and troubleshooting for reproducible results.

• Faropenem Sodium, AMR, and Rational Use

  2026-08-29

  The reference article frames oral faropenem as both a useful broad-spectrum penem antibiotic and a potential antimicrobial-stewardship problem. Its central contribution is linking oral convenience, expanding consumption, uncertain susceptibility interpretation, and reported cross-resistance with carbapenems to the need for laboratory-guided use.

• Calpain Inhibitor I, ALLN: Practical Guide

  2026-08-28

  Calpain Inhibitor I, ALLN (A2602) is a research reagent for probing calpain I/II and cathepsin B/L activity in apoptosis, inflammation, and ischemia-reperfusion workflows. It helps test whether cysteine-protease activity contributes to an observed phenotype, but it should be used as a mechanistic perturbation in validated laboratory models—not as a diagnostic or therapeutic product.

• Sodium Dicloxacillin Monohydrate: PK/PD Assay Logic

  2026-08-28

  Sodium dicloxacillin monohydrate can serve as more than an MSSA antibiotic control: it enables compartment-aware interpretation of exposure, intracellular activity, and time-dependent pharmacodynamics. This guide translates published dicloxacillin findings into stronger assay-design decisions.

• Natural Compounds Against SARS-CoV-2: Docking Evidence

  2026-08-27

  Eskandari’s 2022 study combined virtual screening, molecular docking, and molecular dynamics to evaluate vitamin-derived compounds against both the SARS-CoV-2 main protease and the spike-protein receptor-binding domain. The results nominate overlapping and target-specific compounds, while also illustrating how computational binding predictions can guide—but not replace—biochemical and cellular validation in antiviral therapeutics research.

• Cinoxacin: Mechanism, Spectrum, and Clinical Evidence

  2026-08-27

  The reference paper presents Cinoxacin as a DNA synthesis-inhibiting quinolone antibiotic with rapid urinary exposure, activity against important Enterobacteriaceae, and a clinical role in initial and recurrent bacterial urinary tract infections. Its integrated discussion of antimicrobial susceptibility, pharmacokinetics, adverse reactions, and therapeutic outcomes remains useful for interpreting urinary tract infection research and designing comparative laboratory studies.

• Propranolol Beyond β-Blockade: A Translational Playbook

  2026-08-26

  Propranolol is more than a cardiovascular tool: its non-selective β-adrenergic receptor blockade connects receptor pharmacology with adipose metabolism, inflammatory signaling, and neurobehavioral research. This article translates recent burn-injury metabolomics into practical study-design guidance for researchers evaluating cardiovascular regulation, emotional memory modulation, hypertension treatment, and essential tremor therapy.

• Gepotidacin in Uncomplicated UTI: EAGLE-2 and EAGLE-3

  2026-08-26

  The EAGLE-2 and EAGLE-3 phase 3 trials evaluated oral gepotidacin against nitrofurantoin for uncomplicated urinary tract infection using a rigorous double-blind, double-dummy non-inferiority design. Gepotidacin was non-inferior in both studies and superior in EAGLE-3, supporting further development of a first-in-class oral antibiotic with a distinct bacterial topoisomerase mechanism.

8048 records 6/537 page Previous Next First page 上5页 678910 下5页 Last page